Lille (France), Cambridge (Massachusetts, United States); September 28, 2026 – GENFIT (Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its first half 2026 financial results and provided a corporate update.
Read more at globenewswire.comGENFIT Reports First-Half 2026 Financial Results and Provides Corporate Update
Barchart·09/28/2026 12:51:00
語音播報
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.